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The sodium and chloride coupled y-aminobutyric acid (GABA) transporter purified from rat brain, belongs to a superfamily of neurotransmitter 
transporters. They are involved in the termination of synaptic transmission and are predicted to have 12 membrane spanning a-helices with both 
amino- and carboxyl-termini oriented toward the cytoplasm. In order to define the domains not required for functional expression, we have 
constructed and expressed a series of deletion mutants in GAT-1, the cDNA clone encoding for the transporter. Transporters truncated at either 
end until just a few amino-acids distance from the beginning of helix I and the end of helix 12, retain their ability to catalyze sodium and 
chloride-dependent GABA transport. 
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1. INTRODUCTION 
The GABA, transporter is located in nerve terminals 
[l] and catalyses coupled electrogenic uptake of the neu- 
rotransmitter with 2 or 3 sodium and one chloride ion 
[224]. The transporter has been purified to near homo- 
geneity using a rapid reconstitution assay and is an 80 
kDa glycoprotein which represents 0.1% of the mem- 
brane protein [5,6]. It contains 599 amino acids and is 
predicted to have twelve putative membrane spanning 
CI helices with both amino- and carboxyl termini ori- 
ented toward the cytoplasm [7]. It is the first described 
member [7] of a large superfamily of neurotransmitter 
transporters [8] and is inhibited by ACHC but not by 
p-alanine [9]. The physiological role of these trans- 
porters is to terminate the overall process of synaptic 
transmission [l&12]. 
Often transporter molecules also contain domains 
which are not required for transport. For instance, in 
the case of the anion transporter from erythrocytes [13] 
and the sodium-proton exchanger [14], a substantial 
part of the molecule is required for binding to the cy- 
toskeleton, whereas transport activity resides in a differ- 
ent domain. We have shown that upon treatment of the 
GABA, transporter with proteases, fragments of 60-65 
kDa can be isolated. which are functional and truncated 
at their amino- and carboxyl termini [15,16]. In order 
to define these domains - which are not essential for the 
transport function - we have constructed and expressed 
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a series of deletion mutants in GAT- 1, the cDNA clone 
encoding for the transporter. 
2. MATERIALS AND METHODS 
2.1. Materials 
Polynucleotide kmase, DNA polymerase and DNA ligase (all from 
T4) were from Boehringer. Restriction enzymes were from New Eng- 
land Biolabs and Boehringer. Sequenase kits (version 2.0) were from 
United States Biochemicals. [a-‘SS]dATP (1,000 Ci/mmol) and 
[‘Slmethionine (1,000 Ci/mmol) were from Amersham. [-‘H]GABA 
(47.6 Ci/mmol) was from the Nuclear Research Center, Negev, Israel. 
The tissue culture medium, serum, penicillin/streptomycin and L-glu- 
tamine were from Biological Industries, Kibbutz Bet Ha’Emek, Israel. 
Transfection reagent (DOTAP) was from Boehrmger. The vacciniafI7 
recombinant virus was a gift from Dr. Bernard Moss (NIH). Brain 
lipids were prepared from bovine bram as published [17]. Protem 
A-Sepharose CL-4B, asolectin (P-5638, type II S), valinomycin, urid- 
me, cholic acid and all other materials were obtained from Sigma. The 
antiserum against residues 571-586 of the GAT-1 transporter; 
IQPSEDIVRPENGPEQ (PCooH. part of the carboxy terminal), the 
P,,, peptide as well as P,,,_,; VVEFWERNMHQMTDGLDK 
(part of the loop connecting helices 3 and 4) were generous gifts from 
Dr. Remhard Jahn (Yale University Medical School, New Haven, 
CT) 
2.2. Methods 
2.2.1.’ Site directed mutagenesis 
The original GAT clone contains about 2 kb of 3’ untranslated 
region [7]. We have eliminated this sequence as follows: the clone was 
digested with PsrI and with S&I and the 5 kb fragment was isolated 
after agarose electrophoresis. A synthetic linker was prepared by an- 
nealing primers [5’-CCTACATCTAGGGGTACAGCTGCA-37 and 
[5’-GCTGTACCCCTAGATGTAGG-31. The product was ligated 
with the 5 kb fragment and was used to transform E. coli strain DH-5. 
The closed plasmid DNA was isolated from one of the transformants. 
This cDNA, pT7-GAT-1, contains the open reading frame of GAT-1 
behind the T7 promoter with the natural stop-codon TAG followed 
by 8 bases before reaching the PstI site of the polylinker of pBluescript 
SK, and is fully active when expressed using the vaccinia/T7 recombi- 
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nant virus. Site-directed mutagenesis was performed basIcally as de- 
scribed [18]. The above DNA was used to transform E coli CJ 236 to 
ampicillin resistance. From one of the transformants smgle stranded 
uracil containing DNA was isolated upon growth in a uridine-contain- 
ing medium according to the standard protocol from Stratagene, using 
helper phage R408. This yields the sense strand and consequently the 
mutagenic primers were deslgned to be antisense. 
The following primers were used: 
[5'-GGGCTGCAGCTGTACCCCTAGCCCTTTAGGGTGAGGAACA-3'1 
to make 4X-599; 
[5'-GGGCTGCAGCTGTACCCCTAGGGGATGAGCACCATGGAGG-3'1 
for 4549-599; 
[5'-GGGCTGCAGCTGTACCCCTAAACGTAGCTTCCCATGGTGA-3'1 
for 4528-599; 
[5'-TTCCATGTGTCCCGGTCAGGCGCCATGTCTCGGAGCACGA-3'1 
for A34 1. and 
[5'mGACATGAGGAAGTCGAAGCGCGCCATGTCTCGGAGCACGA-3'1 
for 4349. 
Mutations were verified by DNA sequencing and subcloned mto wild 
type. For deletion mutations A341 and 4349, EcoRI was used and 
orientation was verified using PvuII. Age I was used together with 
ScaI for 4561-599, 4549-599 and 4528-599. The subcloned DNAs 
were sequenced between the sites of the indicated restriction enzymes 
The deletion construct 4576-599 was made after dlgestion of the 
GAT-1 clone by EcoRV and separation of the insert from the vector. 
The insert was ligated into the ClaI site of Bluescript SK which was 
filled in with the Klenow fragment of E. coli DNA polymerase. The 
orientation of the insert was verified using Bgfl. The insert encodes the 
first 576 amino acids followed by arginine and the stopcodon TAA. 
2.2.2. Cell growth and expression 
HeLa cells were cultured in DMEM supplemented with 10% fetal 
calf serum (heat-inactivated), 100 Units/ml penicillin. 100 @ml strep- 
tomycin and 2 mM glutamine. Infection with recombinant vacciniaiT7 
virus vTF7-3 and subsequent transfection with plasmid DNA was 
done exactly as described [9]. GABA transport and immunoprecipi- 
tation were done as published previously. Protein was determined 
after lysis of the cells by addition of 2% NaZCO, in 0. I N NaOH (200 
@/well). Aliquots were taken for protein determmation [19]. SDS- 
PAGE was as described [20] using a 4% stacking and 10% separating 
gel. Size standards (Pharmacia) were run in parallel and visualised by 
Coomassie blue staining. For each reconstitution experiment infected/ 
transfected cells from 2 large wells (3 cm diameter) were used. They 
were twice washed with 1 ml of PBS and taken up in a small volume 
of PBS using a rubber policeman. To 20 ~1 of this suspension were 
added (in this order) 2.5 ~1 of saturated ammonium sulfate (pH of 
20-fold dilution equals 7.5) and 1.9 ~1 of 20% cholic acid (neutralised 
by NaOH). After a 10 min incubation on ice, the mixture was centri- 
fuged in an Ependorff centrifuge for 3 min. The supernatant (20 ~1) 
was reconstituted with asolectitibrain lipids using spin columns and 
transport was measured exactly as described [5]. 
3. RESULTS AND DISCUSSION 
The transporter encoded by GAT-1 has a predicted 
open reading frame of 599 amino acids, and the inward 
oriented carboxyl tail begins at threonine-558. In order 
to assess its possible importance in the functional ex- 
pression of the transporter, a number of progressive 
deletions from the terminus were constructed cutting 
with restriction enzymes and subcloning (4576-599) or 
by loop-out site-directed mutagenesis [18]. These in- 
cluded A561-599,4549-599 and 4528-599 (the first res- 
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Fig. 1. Time course of [3H]GABA transport in vaccinia/T7_infected 
HeLa cells transfected with pBluescript containing cDNA encoding 
for transporters truncated from the carboxyl terminal. HeLa cells were 
infected with vTF7-3 and transfected with pT7-GAT-I (wild type. l ). 
4576-599 (m). 4561-599 (0) or 4549-599 (A). 50 fig of protein was 
present m each well. Duplicate time points were taken. but m some 
of the cases the error was so small that they fell within the width of 
the symbol. 
idue number indicates the last amino acid before the 
natural stop codon TAG). After the deletions were ver- 
ified by sequencing, the mutant cDNA was expressed in 
HeLa cells using the recombinant vaccinia/T7 virus [21] 
as described [9,22]. Deletion of more than half of the tail 
(4576599) does not affect GABA transport, and even 
its almost complete removal (4561-599) still leaves 
about 25% of the activity (Fig. 1). On the other hand 
deletion of part of helix 12 (4549-599) causes abolish- 
ment of transport activity (Fig. 1). The same result is 
obtained when all of helix 12 is deleted (4528-599, data 
not shown). In all cases where deletions were functional, 
transport was dependent on both sodium and chloride 
and retained its pharmacological specificity - inhibition 
by ACHC but not by /3-alanine (data not shown). 
Truncation at the amino terminal was performed 
starting from threonine-3, thereby leaving the start 
methionine and alanine- as well as the 5’-upstream 
sequences unaffected. Deletion until proline -42 (A3- 
41) has no effect whatsoever on GABA transport (Fig. 
2). However, deletion until arginine-50 (A349), three 
amino acids from the start of helix 1, results in defective 
transport. 
Defective expression could be due to importance of 
the deleted regions in the activity of the transporter, but 
also to defects in synthesis and/or turnover, or impaired 
targetting. Fig. 3 illustrates that the amounts of the 
transporters truncated at the amino terminus are similar 
to that of the full-length transporter. After transfection 
with the appropriate plasmid DNAs the cells were la- 
belled with [“‘Slmethionine. Subsequently the labelled 
transporters were immunoprecipitated by an antibody 
directed against a sequence located in the carboxyl ter- 
minus of the transporter, but not by preimmune serum 
(Fig. 3). The ‘wild type’ transporter synthesized in this 
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Fig. 2. Time course of [‘HIGABA transport upon expression of GAT- 
1 truncated from the amino terminus. HeLa cells were infected with 
vTF7-3 and transfected with wild type pT7-GAT-1 (+), 43-41 (A) or 
4349 (0). 
system runs as a 67 kDa polypeptide [9]. The truncated 
transporters have a larger mobility, as expected from 
their decreased molecular mass, but they are present at 
similar levels to that of the ‘wild-type’ transporter. As 
an additional control for the specificity of the im- 
munoprecipitation reactions we demonstrated that it 
was abolished by the homologous PcooH peptide 
(against which the antibody was raised) but not by a 
heterologous peptide P189-206 (data not shown). In 
similar experiments - using an antibody raised against 
the whole transporter [6] - we have shown that all the 
transporters truncated from the carboxyl terminal were 
present at similar levels to those of the wild-type trans- 
porter (data not shown). 
The lack of activity observed in some of the deletion 
mutants also does not seem to be due to defective target- 
ing to the plasma membrane. In the absence of high titer 
antibodies against external epitopes -which would ena- 
ble the performance of immunofluorescence studies on 
intact cells - we adopted an alternative approach to this 
issue. As the inactive deletion mutants 4349.4528-599 
and 4549-599 make the truncated transporters, it could 
be located in internal membranes. If this were to be the 
reason for lack of activity, detergent extraction of the 
cells and reconstitution of the solubilized transporters 
should reveal activity in the proteo-liposomes. While 
such a procedure yielded sodium and chloride depend- 
ent GABA transport in the wild type, it did not in the 
case of these mutants as illustrated for A349 and A549- 
599 (Fig. 4). Therefore, it appears that the large major- 
ity of the hydrophilic parts of amino acid carboxyl ter- 
mini are not essential for functional expression. In pro- 
teolysis experiments we performed on the isolated trans- 
porter it appeared that active fragments cleaved at car- 
boxy and amino termini could be isolated [ 15,161. The 
reduction in apparent molecular mass of these frag- 
ments based on the mobility in SDS-PAGE was 15-20 
kDa. This would predict that several a-helices are not 
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Fig. 3. Immunoprecipitation of wild type and amino terminal trun- 
cated GAT-1 proteins synthesized in vivo in HeLa cells. The cells were 
labelled with [%]methronine, lysed and immunoprecipitated with anti- 
ProoH (even lanes) or preimmune serum from the same rabbit (odd 
lanes). GAT-1 expression was directed in the vacciniaIT7 expression 
system by pT7-TAT-1 (wild type, lanes 7 and 8). 4341 (lanes 3 and 
4) or 4349 (lanes 5 and 6). A control-recombinant virus alone was 
also run (lanes 1 and 2). 
required for the transport function, which was puzzling 
in view of the high conservation of helices 1 and 2 within 
the superfamily, as well as the presence of several criti- 
cal amino acids in helix 1 as shown by site-directed 
mutagenesis [23,24]. In this paper we have defined the 
boundaries of the termini which can be cleaved off with- 
out impairing function. As the last few amino acids 
adjacent to helices 1 and 12 seem to be important for 
transport function per se, it appears that the proteolysis 
data can best be interpreted in view of the well-known 
0 2 4 6 8 10 12 
TIME (min) 
Fig. 4. Time course of [3H]GABA transport in liposomes inlaid with 
solubilized HeLa cell membrane proteins. Upon infection of the cells 
with vTF7-3, they were transfected with pT7-GAT-1 (A), 45499599 (0) 
or 43-49 (@). The cells were treated with cholate and solubilized 
proteins were reconstituted as described in Section 2. 10 fig of protein 
was used for each time point. 
43 
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atypical mobility of hydrophobic proteins as compared 
with that of the standard proteins [25]. 
It is of interest to note that truncation of most of the 
hydrophilic part of the carboxyl terminus of the facili- 
tated glucose transporter does cause a complete loss of 
the transport function [26]. On the other hand in the 
proton-coupled lactose transporter of E. coli, the car- 
boxy1 terminal can be cleaved off almost entirely with- 
out loss of function [27], similar to the situation de- 
scribed here. The critical role of the hydrophilic amino 
acids adjacent o helix 1 in transporter function remains 
to be elucidated. 
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